<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41852">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01894724</url>
  </required_header>
  <id_info>
    <org_study_id>CS-1.0</org_study_id>
    <nct_id>NCT01894724</nct_id>
  </id_info>
  <brief_title>Targeted Hypothermia During Cardiac Surgery</brief_title>
  <official_title>Targeted Cerebral Hypothermia During Cardiac Surgery: A Feasibility Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuroSave Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeuroSave Inc.</source>
  <oversight_info>
    <authority>Australia: Human Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study designed to evaluate the safety and feasibility of the NeuroSave device to
      rapidly reduce brain temperature while maintaining the brain at a lower temperature than the
      body core during cardiac surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Freedom from major adverse events related to the use of the NeuroSave device</measure>
    <time_frame>Surgery through discharge (up to 5 days post-surgery)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain-core temperature differential during cardiac surgery</measure>
    <time_frame>Continuously assessed over course of cardiac surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>NeuroSave Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Targeted Hypothermia with NeuroSave Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeuroSave device</intervention_name>
    <arm_group_label>NeuroSave Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â‰¥18 years of age

          -  Undergoing coronary revascularization or valvular cardiac surgery

          -  The study patient or the study patient's legal representative has been informed of
             the nature of the study, agrees to its provisions and has provided written informed
             consent as approved by the Human Research Ethics Committee (HREC) of the respective
             clinical site

          -  The study patient agrees to comply with all study -related procedures

        Exclusion Criteria:

          -  Women known or suspected to be pregnant (as confirmed by a pregnancy test for all
             women of child-bearing age)

          -  Past history of cerebrovascular accident (stroke or TIA)

          -  History of clinically diagnosed active psychiatric conditions

          -  Emergency or salvage cardiac valve operations

          -  Body weight &lt; 50 kg

          -  Leukopaenia (WBC &lt; 3000 cell/mL), anaemia (Hgb &lt; 11g/dL), Thrombocytopaenia (Plt &lt;
             50,000 cell/mL)

          -  Active upper GI bleeding within 3 months (90 days) prior to procedure

          -  Renal insufficiency (creatinine &gt; 265 micromol/L) and/or renal replacement therapy at
             the time of screening

          -  Estimated life expectancy &lt; 12 months (365 days)

          -  Structural abnormality or disease of nose, mouth, pharynx and oesophagus (excluding
             gastric reflux oesophagus disease),

          -  Currently participating in an investigational drug or another device study that would
             potentially impact the results of this study as determined by the PI. Note: Trials
             requiring extended follow-up for products that were investigational, but have since
             become commercially available, are not considered investigational trials
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvanna Marasco</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Alfred Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margaret Qualye</last_name>
    <phone>03 90768040</phone>
    <email>M.Quayle@alfred.org.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Silvanna Marasco, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Daly, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 11, 2014</lastchanged_date>
  <firstreceived_date>June 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypothermia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
